SAT-128 Prospective 1-year Menstrual CycleBreast Tenderness and Swelling Experiences—data from healthy regularly cycling women initially proven normally ovulatory on two consecutive cycles
Jerilynn C Prior, Sonia Shirin, Mary Wood, Azita Goshtasebi
breast tenderness swelling menstrual cycle ovulatory status, Prior JC premenstrual breast symptoms ovulation prospective study, subclinical ovulatory disturbances breast changes progesterone, menstrual cycle diary breast tenderness score luteal phase, quantitative basal temperature QBT ovulation classification, short luteal phase anovulation breast symptom differences, premenstrual symptoms healthy cycling women one year prospective, cyclic progesterone therapy ovulatory disturbance identification, breast swelling follicular vs luteal phase women runners, within-woman comparison ovulatory anovulatory breast tenderness
DOI 10.1210/jendso/bvaf149.1978 10.1210/jendso/bvaf149.1978
Cite this article
Wood, M., Prior, J. C., Shirin, S., & Goshtasebi, A. (2025). SAT-128 Prospective 1-year Menstrual CycleBreast Tenderness and Swelling Experiences—data from healthy regularly cycling women initially proven normally ovulatory on two consecutive cycles. *Journal of the Endocrine Society*, *9*(Supplement_1). https://doi.org/10.1210/jendso/bvaf149.1978
Wood M, Prior JC, Shirin S, Goshtasebi A. SAT-128 Prospective 1-year Menstrual CycleBreast Tenderness and Swelling Experiences—data from healthy regularly cycling women initially proven normally ovulatory on two consecutive cycles. Journal of the Endocrine Society. 2025;9(Supplement_1). doi:10.1210/jendso/bvaf149.1978
Wood, M., et al. "SAT-128 Prospective 1-year Menstrual CycleBreast Tenderness and Swelling Experiences—data from healthy regularly cycling women initially proven normally ovulatory on two consecutive cycles." *Journal of the Endocrine Society*, vol. 9, no. Supplement_1, 2025.
Baaske AV et al., 2025
Open Access
Journal of the Endocrine Society
Disclosure: A.V. Baaske: None. S. Shirin: None. C. Bos: None. D. Kalidasan: None. J.C. Prior: None.
Background: Tanner Breast Stage 3 (TB3, at menarche) and Tanner 5 (TB5, once ovulatory cycles establ...
Nelson K et al., 2025
Open Access
Journal of the Endocrine Society
Disclosure: K. Nelson: None. J. Singer: None. A. Pederson: None. D. Kalidasan: None. J. Prior: None.
Polycystic ovary syndrome (PCOS) is an endocrine-metabolic disorder that significantly decreases he...
PCOS > Treatment > Progesterone TherapyPCOS > Treatment > Antiandrogen TherapyPCOS > Quality of Life > Patient-Reported Outcomes
Shirin S et al., 2020
Open Access
Journal of the Endocrine Society
Endometrial cancer1 and oligomenorrhea2 are common risks for women living with androgenic PCOS (WLWP); cyclic progesterone therapy could prevent both. Cyclic oral micronized progesterone therapy (Cycl...
Shirin S et al., 2020
Open Access
Journal of the Endocrine Society
Women living with androgenic PCOS (WLWP) experience unpredictable oligomenorrhea1 and are at increased risk for endometrial cancer2. Oral micronized progesterone (OMP) given cyclically (14 days/cycle ...